Inflammatory Bowel Disease (IBD) Therapeutics - Global Strategic Business Report

The global market for Inflammatory Bowel Disease (IBD) Therapeutics is estimated at US$23.2 Billion in 2023 and is projected to reach US$32.8 Billion by 2030, growing at a CAGR of 5.1% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

The growth in the IBD therapeutics market is driven by several factors, including the increasing prevalence of IBD, technological innovations, and greater awareness and diagnosis of the condition. The rising incidence of IBD globally, particularly in developed regions, is significantly expanding the patient population in need of effective treatments. Technological advancements in biologic therapies and the development of biosimilars are reducing treatment costs and making advanced therapies more accessible. The integration of precision medicine into IBD treatment protocols is leading to more effective and personalized therapeutic approaches, improving patient outcomes and satisfaction. Additionally, the adoption of digital health technologies is facilitating better disease management and patient engagement, driving adherence to treatment plans. Regulatory support for novel therapies and expedited approval processes for new drugs are also contributing to market growth. Moreover, ongoing clinical trials and research into the pathophysiology of IBD are paving the way for the development of next-generation therapeutics, promising even more effective and targeted treatment options in the future. These combined factors underscore the dynamic and rapidly evolving nature of the IBD therapeutics market.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the TNF inhibitors segment, which is expected to reach US$14.0 Billion by 2030 with a CAGR of a 5.9%. The Anti-integrin segment is also set to grow at 4.9% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, estimated at $6.1 Billion in 2023, and China, forecasted to grow at an impressive 8.2% CAGR to reach $7.6 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Inflammatory Bowel Disease (IBD) Therapeutics Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Inflammatory Bowel Disease (IBD) Therapeutics Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Inflammatory Bowel Disease (IBD) Therapeutics Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of major players such as 4SC AG, Abbott Nutrition, AbbVie, Inc., and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 69 Featured):

• 4SC AG
• Abbott Nutrition
• AbbVie, Inc.
• Ablynx NV
• Active Biotech AB
• Alfasigma S.p.A.
• Allergan PLC
• Allergan PLC
• Amgen, Inc.
• Astellas Pharma, Inc.
• AstraZeneca PLC
• Athersys, Inc.
• Atlantic Healthcare plc
• Avaxia Biologics, Inc.
• Biosafe Systems, LLC
• Boehringer Ingelheim GmbH
• Cadila Healthcare Ltd.
• Celgene Corporation
• Celltrion, Inc.
• Cipla Ltd.
• Coherus Biosciences, Inc.
• Cosmo Pharmaceuticals NV
• Dr. Falk Pharma GmbH
• EA Pharma Co., Ltd.
• Eddingpharm
• EPIRUS Biopharmaceuticals, Inc.
• F. Hoffmann-La Roche AG
• F. Hoffmann-La Roche AG
• Galapagos NV
• Giaconda Ltd.
• Google LLC
• Immunic, Inc.
• InDex Pharmaceuticals Holding AB
• Infinity Pharmaceuticals, Inc.
• Ionis Pharmaceuticals, Inc.
• Janssen Biotech, Inc.
• Johnson & Johnson
• Kissei Pharmaceutical Co., Ltd.
• LG Sciences
• Lupin Ltd.
• Mochida Pharmaceutical Co., Ltd.
• Mylan Pharmaceutical Pvt. Ltd.
• Neovacs SA
• Nogra Pharma Limited
• NovaMedica LLC
• Novartis International AG
• Osiris Therapeutics, Inc.
• Otsuka Pharmaceutical Co., Ltd.
• PAR Pharmaceutical Companies, Inc.
• PendoPharm, Inc.
• Perrigo Company PLC
• Pfenex, Inc.
• Pfizer, Inc.
• Pharmascience Inc.
• Pluristem Therapeutics, Inc.
• Qu Biologics Inc.
• Quest Diagnostics, Inc.
• RedHill Biopharma Ltd.
• Reliance Life Sciences
• Salix Pharmaceuticals, Inc.
• Sandoz International GmbH
• Sanofi
• Sequella, Inc.
• Soligenix, Inc.
• Takeda Pharmaceutical Co., Ltd.
• Teva Pharmaceutical Industries Ltd.
• Toray Industries, Inc.
• Torrent Pharmaceuticals Ltd.
• UCB SA
• Zeria Pharmaceutical Co., Ltd.